Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Arrowhead Pharmaceuticals Inks Global Licensing And Collaboration Agreement With Novartis For ARO-SNCA For Synucleinopathies, Such As Parkinson's Disease; Arrowhead Will Receive $200M As An Upfront Payment And Is Eligible To Receive Up To $2B In Milestone Payments Plus Commercial Sales Royalties

Author: Benzinga Newsdesk | September 02, 2025 07:32am

Upon closing, Arrowhead will receive an upfront payment of $200 million
Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead's preclinical stage siRNA therapy for the treatment of synucleinopathies, such as Parkinson's Disease, plus additional collaboration targets

Posted In: ARWR NVS